James O'Brien

James O'Brien

Finansdirektör/CFO på MESOBLAST LIMITED
59 år
Health Technology
Commercial Services
Consumer Services

Profil

James M.
O'Brien
is currently Chief Financial Officer at Mesoblast Ltd. since 2025.
Former positions include Chief Financial Officer at Faron Pharmaceuticals Oy from 2023 to 2024, Chief Financial Officer at Cognition Therapeutics, Inc. from 2019 to 2022, Executive Vice President-Finance at Enzo Biochem, Inc. from 2014 to 2019, Vice President & Corporate Controller at Allergan UC from 2010 to 2013, Vice President at Takeda Pharmaceutical Co., Ltd. in 2010, Chief Accounting Officer at U.S.I.
Holdings Corp.
from 2008 to 2009, Vice President & Controller at Aptuit LLC from 2005 to 2007, Chief Accountant at Purdue Pharma LP, and Principal at both Bristol Myers Squibb Co. and PricewaterhouseCoopers LLP.
Education includes undergraduate studies at George Washington University and an MBA from Fordham University.

Aktiva positioner av James O'Brien

FöretagPositionStart
MESOBLAST LIMITED Finansdirektör/CFO 2025-11-17

Tidigare kända positioner av James O'Brien

FöretagPositionSlut
FARON PHARMACEUTICALS OY Finansdirektör/CFO 2024-04-15
COGNITION THERAPEUTICS, INC. Finansdirektör/CFO 2022-08-12
ENZO BIOCHEM, INC. Företagsledare/Principal 2019-11-03
ALLERGAN PLC Comptroller/Controller/Revisor -
TAKEDA PHARMACEUTICAL COMPANY LIMITED Företagsledare/Principal 2010-08-01
Se detaljerna i James O'Briens erfarenhet

James O'Briens utbildningar

Erfarenheter
Innehade positioner

Aktiva

Inaktiva

Börsnoterade företag

Privata företag

Relationer

28

Första gradens relationer

13

Företag kopplade till första graden

Man

Kvinna

Styrelseledamöter

Chefer

Kopplade företag

Privata företag13

Health Technology

Health Technology

Commercial Services

Finance

Commercial Services

Health Technology

Consumer Services

Distribution Services

Consumer Services

Health Technology

Health Technology

Health Technology

Health Technology

  1. Börsen
  2. Insiders
  3. James O'Brien
SENASTE TIDEN | -40%: De bästa verktygen för prenumeranter för att identifiera morgondagens bästa investeringar!
d
:
:
TA FÖRDEL AV DET NU